Not quite comparable since death from any cause may have

Not quite comparable since death from any cause may have included patients who were not mechanically ventilated. Which actually makes it worse for tocilizumab since leronlimab had a tougher patient population.

Quote:

The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group

Quote:

Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, –5.2 to 7..